HK1199736A1 - Poly(vinyl ester) polymers for in vivo nucleic acid delivery - Google Patents

Poly(vinyl ester) polymers for in vivo nucleic acid delivery Download PDF

Info

Publication number
HK1199736A1
HK1199736A1 HK15100132.2A HK15100132A HK1199736A1 HK 1199736 A1 HK1199736 A1 HK 1199736A1 HK 15100132 A HK15100132 A HK 15100132A HK 1199736 A1 HK1199736 A1 HK 1199736A1
Authority
HK
Hong Kong
Prior art keywords
poly
polymer
vinyl ester
polynucleotide
random copolymer
Prior art date
Application number
HK15100132.2A
Other languages
English (en)
Chinese (zh)
Inventor
‧維基菲爾德
D‧H‧维基菲尔德
‧羅西
N‧罗西
‧謝赫
D‧谢赫
Original Assignee
箭头研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 箭头研究公司 filed Critical 箭头研究公司
Publication of HK1199736A1 publication Critical patent/HK1199736A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
    • C08F20/10—Esters
    • C08F20/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F218/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid
    • C08F218/02—Esters of monocarboxylic acids
    • C08F218/04—Vinyl esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F218/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid
    • C08F218/02—Esters of monocarboxylic acids
    • C08F218/04—Vinyl esters
    • C08F218/10—Vinyl esters of monocarboxylic acids containing three or more carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F218/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid
    • C08F218/22—Esters containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
HK15100132.2A 2011-08-26 2012-08-23 Poly(vinyl ester) polymers for in vivo nucleic acid delivery HK1199736A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161527703P 2011-08-26 2011-08-26
US61/527,703 2011-08-26
US13/592,393 2012-08-23
US13/592,393 US8932572B2 (en) 2011-08-26 2012-08-23 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
PCT/US2012/051968 WO2013032829A1 (en) 2011-08-26 2012-08-23 Poly(vinyl ester) polymers for in vivo nucleic acid delivery

Publications (1)

Publication Number Publication Date
HK1199736A1 true HK1199736A1 (en) 2015-07-17

Family

ID=47756738

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100132.2A HK1199736A1 (en) 2011-08-26 2012-08-23 Poly(vinyl ester) polymers for in vivo nucleic acid delivery

Country Status (12)

Country Link
US (3) US8932572B2 (OSRAM)
JP (1) JP2014531476A (OSRAM)
KR (1) KR20140051357A (OSRAM)
CN (1) CN104024328A (OSRAM)
AU (1) AU2012300476B2 (OSRAM)
BR (1) BR112014004585A2 (OSRAM)
CA (1) CA2842039A1 (OSRAM)
HK (1) HK1199736A1 (OSRAM)
IL (1) IL231146A0 (OSRAM)
MX (1) MX2014001971A (OSRAM)
PH (1) PH12014500214A1 (OSRAM)
WO (1) WO2013032829A1 (OSRAM)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
CN104024328A (zh) * 2011-08-26 2014-09-03 箭头研究公司 用于体内核酸递送的聚(乙烯基酯)聚合物
EP2751270B1 (en) 2011-08-29 2018-08-22 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US8796405B2 (en) 2012-01-18 2014-08-05 Wisconsin Alumni Research Foundation Degradable polycations derived from amino acid vinyl esters
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
BR112014004528A2 (pt) * 2012-04-18 2019-09-24 Arrowhead Res Corp polímeros de poli(acrilato) para entrega de ácido nucleico in vivo
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
SG11201506805QA (en) 2013-02-28 2015-09-29 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
CN105263476A (zh) * 2013-03-13 2016-01-20 库尔制药开发公司 用于治疗炎症的免疫修饰性颗粒
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112015027322A8 (pt) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Compostos antissenso conjugados e sua utilização
KR20160035081A (ko) 2013-08-07 2016-03-30 애로우헤드 리서치 코오포레이션 생체 내에서 RNAi 유발제를 종양 세포로 전달하기 위한 폴리콘주게이트
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US9926556B2 (en) 2014-04-28 2018-03-27 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
MX380866B (es) 2014-05-01 2025-03-12 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del factor b del complemento.
HUE052709T2 (hu) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
BR122020024446B8 (pt) 2014-05-01 2022-06-28 Ionis Pharmaceuticals Inc Compostos para modulação da expressão do receptor do hormônio de crescimento
EP3845547A1 (en) 2014-05-01 2021-07-07 Ionis Pharmaceuticals, Inc. Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Ｈｉｆ２α基因表現之組合物及方法
ES2917181T3 (es) 2015-07-10 2022-07-07 Ionis Pharmaceuticals Inc Moduladores de diacilglicerol aciltransferasa 2 (DGAT2)
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
EP3353328A4 (en) 2015-09-24 2019-06-12 Ionis Pharmaceuticals, Inc. MODULATORS OF KRAS EXPRESSION
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN109310751A (zh) 2015-10-22 2019-02-05 摩登纳特斯有限公司 广谱流感病毒疫苗
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
EA201890999A1 (ru) 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. Вакцина против вируса простого герпеса
AU2016341311B2 (en) 2015-10-22 2023-11-16 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
CN113952353A (zh) 2015-11-06 2022-01-21 Ionis制药公司 调节载脂蛋白(a)表达
PT4119569T (pt) 2015-11-06 2024-10-23 Ionis Pharmaceuticals Inc Compostos antissentido conjugados para utilização em terapia
PL3394093T3 (pl) 2015-12-23 2022-05-16 Modernatx, Inc. Metody stosowania polinukleotydów kodujących ligand ox40
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
KR102426487B1 (ko) 2016-06-06 2022-07-27 애로우헤드 파마슈티컬스 인코포레이티드 5'-시클로-포스포네이트 변형된 뉴클레오티드
PE20190513A1 (es) 2016-07-15 2019-04-10 Ionis Pharmaceuticals Inc Compuestos y metodos para la modulacion de smn2
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
US10294474B2 (en) 2016-09-02 2019-05-21 Arrowhead Pharmaceuticals, Inc. Targeting ligands
CN109661233A (zh) 2016-10-06 2019-04-19 Ionis 制药公司 缀合低聚化合物的方法
TW202436621A (zh) 2017-01-10 2024-09-16 美商愛羅海德製藥公司 α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
CN110234326B (zh) 2017-01-30 2024-11-12 箭头药业股份有限公司 用于抑制因子xii基因表达的组合物和方法
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019051402A1 (en) 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. RNA INTERFERENCE AGENTS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
CA3074320A1 (en) 2017-09-14 2019-03-21 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
US11492624B2 (en) 2017-10-17 2022-11-08 Arrowheads Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
JP2021511072A (ja) 2018-01-15 2021-05-06 アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｄｎｍ２発現のモジュレーター
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
MY204000A (en) 2018-05-09 2024-07-31 Ionis Pharmaceuticals Inc Compounds and methods for reducing fxi expression
EP3823725A4 (en) 2018-07-17 2023-05-10 Aronora, Inc. METHODS FOR SAFELY REDUCING THROMBOPOIETIN
WO2020033748A1 (en) 2018-08-08 2020-02-13 Arcturus Therapeutics, Inc. Compositions and agents against nonalcoholic steatohepatitis
TWI869213B (zh) 2018-09-19 2025-01-01 美商Ionis製藥公司 Pnpla3表現之調節劑
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
MX2021007503A (es) 2018-12-21 2021-08-05 Ionis Pharmaceuticals Inc Moduladores de la expresion de hsd17b13.
CA3120580A1 (en) 2019-01-09 2020-07-16 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
TWI872048B (zh) 2019-02-07 2025-02-11 美商艾羅海德製藥公司 用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑
US20220305117A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
US20220305107A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
JP7757277B2 (ja) 2019-10-14 2025-10-21 アストラゼネカ・アクチエボラーグ Ｐｎｐｌａ３発現のモジュレーター
JP7446443B2 (ja) 2020-02-28 2024-03-08 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｓｍｎ２を調節するための化合物及び方法
KR20220158011A (ko) 2020-03-26 2022-11-29 애로우헤드 파마슈티컬스 인코포레이티드 PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
BR112022021462A2 (pt) 2020-04-21 2023-01-17 Flagship Pioneering Inc Moléculas bifuncionais e métodos de sua utilização
JP2023540806A (ja) 2020-09-11 2023-09-26 アローヘッド ファーマシューティカルズ インコーポレイテッド 骨格筋への送達プラットフォームおよび使用の方法
WO2022056266A2 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
KR20230066587A (ko) 2020-09-11 2023-05-16 애로우헤드 파마슈티컬스 인코포레이티드 치료제의 전달을 위한 지질 접합체
KR20230108728A (ko) 2020-11-18 2023-07-18 아이오니스 파마수티컬즈, 인코포레이티드 앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
MX2023011909A (es) 2021-04-08 2023-10-18 Arrowhead Pharmaceuticals Inc Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso.
AU2022262794A1 (en) 2021-04-23 2023-11-02 Beth Israel Deaconess Medical Center, Inc. Glycan modified nucleic acids, methods of preparation, and therapeutic uses
CN117858949A (zh) 2021-05-28 2024-04-09 箭头药业股份有限公司 用于抑制粘蛋白5AC(MUC5AC)的表达的RNAi试剂、其组合物及其使用方法
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
CA3233755A1 (en) 2021-10-01 2023-04-06 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2023245060A2 (en) 2022-06-15 2023-12-21 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
AU2024240837A1 (en) 2023-03-21 2025-09-11 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of complement factor b (cfb) pharmaceutical compositions thereof, and methods of use
TW202448484A (zh) 2023-04-20 2024-12-16 美商雅迪克斯製藥公司 Ｍａｐｔ調節組合物及其使用方法
TW202502385A (zh) 2023-05-12 2025-01-16 美商雅迪克斯製藥公司 Ｎｍｄａ配位體結合之化合物及其用途
AU2024279767A1 (en) 2023-05-26 2025-12-04 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
WO2024263694A1 (en) 2023-06-20 2024-12-26 Adarx Pharmaceuticals, Inc. Lrrk2-modulating compositions and methods of use thereof
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
TW202530408A (zh) 2023-09-29 2025-08-01 美商英西特羅公司 用於治療非酒精性脂肪肝病的組合物與方法
WO2025137384A1 (en) 2023-12-20 2025-06-26 Arrowhead Pharmaceuticals, Inc. Methods and reagents for improved oligonucleotide synthesis
US20250297260A1 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
WO2025226980A2 (en) 2024-04-25 2025-10-30 Insitro, Inc. Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0359003A (ja) * 1989-07-27 1991-03-14 Mitsubishi Kasei Corp 酸感受性ポリマー
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
TW316266B (OSRAM) 1993-07-30 1997-09-21 Commw Scient Ind Res Org
US6291620B1 (en) 1994-11-09 2001-09-18 E. I. Du Pont De Nemours And Company Polymer synthesis
JPH0931057A (ja) * 1995-07-21 1997-02-04 Eiweiss Kk プロリン骨格を有するビニルエーテル、その製法およびその重合体ならびに共重合体
ATE210684T1 (de) 1996-07-10 2001-12-15 Du Pont POLYMERISATION MIT ßLIVINGß KENNZEICHEN
JP4138024B2 (ja) 1997-04-23 2008-08-20 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー マクロモノマーの合成方法
DE69840423D1 (de) 1997-07-21 2009-02-12 Commw Scient Ind Res Org Synthese von dithioester-kettentransferagentien
BR9815179A (pt) 1997-12-18 2000-10-10 Du Pont Processo para produzir um polìmero, polìmero, composição de revestimento e agente de transferência de cadeia.
WO2000075162A1 (en) * 1999-06-07 2000-12-14 Mirus Corporation A compound containing a labile disulfide bond
JP4751556B2 (ja) * 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
US7816337B2 (en) * 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
CA2670749A1 (en) * 2006-12-05 2008-06-12 Landec Corporation Drug delivery
US8999323B2 (en) * 2007-11-23 2015-04-07 Technische Universität Wien Composition that can be cured by polymerisation for the production of biodegradable, biocompatible, cross-linkable polymers on the basis of polyvinyl alcohol
AU2009246327B8 (en) 2008-05-13 2013-10-03 Phaserx, Inc. Diblock copolymers and polynucleotide complexes thereof for delivery into cells
AU2009313358B2 (en) 2008-11-06 2013-06-06 Phaserx, Inc. Multiblock copolymers
NZ594255A (en) 2009-01-23 2013-09-27 Commw Scient Ind Res Org RAFT polymerisation
RS54578B1 (sr) 2010-02-24 2016-06-30 Arrowhead Research Corporation Preparati za ciljano dopremanje sirnk
US20110224377A1 (en) * 2010-03-11 2011-09-15 Mahesh Kalyana Mahanthappa Poly(vinyl ester) block copolymers
US9376523B2 (en) 2010-03-19 2016-06-28 Wisconsin Alumni Research Foundation Poly(vinyl alcohol)-poly(vinyl ester) block copolymers
US20130236968A1 (en) 2010-06-21 2013-09-12 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
CN104024328A (zh) * 2011-08-26 2014-09-03 箭头研究公司 用于体内核酸递送的聚(乙烯基酯)聚合物

Also Published As

Publication number Publication date
AU2012300476B2 (en) 2016-03-24
WO2013032829A1 (en) 2013-03-07
JP2014531476A (ja) 2014-11-27
AU2012300476A1 (en) 2014-01-23
US20150110732A1 (en) 2015-04-23
US9474804B2 (en) 2016-10-25
CN104024328A (zh) 2014-09-03
MX2014001971A (es) 2014-03-31
US20130121954A1 (en) 2013-05-16
US8932572B2 (en) 2015-01-13
IL231146A0 (en) 2014-04-30
PH12014500214A1 (en) 2019-03-22
BR112014004585A2 (pt) 2017-06-13
US9089611B2 (en) 2015-07-28
KR20140051357A (ko) 2014-04-30
CA2842039A1 (en) 2013-03-07
US20150283256A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
US9089611B2 (en) Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US8933047B2 (en) Poly(acrylate) polymers for in vivo nucleic acid delivery
CN103547272B (zh) 基于肽的体内siRNA递送系统
CN102869774B (zh) 用于靶向递送siRNA的组合物
CN103491982B (zh) 具有酶敏感性连接的多核苷酸体内递送偶联物
US8426554B2 (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
HK1194691A (en) Poly(acrylate) polymers for in vivo nucleic acid delivery
EP2807216A1 (en) Poly(vinyl ester) polymers for in vivo nucleic acid delivery
EP2838544A1 (en) Poly(acrylate) polymers for in vivo nucleic acid delivery
HK1188947B (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
HK1188947A (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
HK1191566B (en) Peptide-based in vivo sirna delivery system
HK1191566A (en) Peptide-based in vivo sirna delivery system